Cathepsin V regulates cell cycle progression and histone stability in the nucleus of breast cancer cells

Sereesongsaeng, Naphannop and Burrows, James F. and Scott, Christopher J. and Brix, Klaudia and Burden, Roberta E. (2023) Cathepsin V regulates cell cycle progression and histone stability in the nucleus of breast cancer cells. Frontiers in Pharmacology, 14. ISSN 1663-9812

[thumbnail of pubmed-zip/versions/1/package-entries/fphar-14-1271435/fphar-14-1271435.pdf] Text
pubmed-zip/versions/1/package-entries/fphar-14-1271435/fphar-14-1271435.pdf - Published Version

Download (2MB)

Abstract

Introduction: We previously identified that Cathepsin V (CTSV) expression is associated with poor prognosis in ER+ breast cancer, particularly within the Luminal A subtype. Examination of the molecular role of the protease within Luminal A tumours, revealed that CTSV promotes tumour cell invasion and proliferation, in addition to degradation of the luminal transcription factor, GATA3, via the proteasome.

Methods: Cell line models expressing CTSV shRNA or transfected to overexpress CTSV were used to examine the impact of CTSV on cell proliferation by MTT assay and flow cytometry. Western blotting analysis was used to identify the impact of CTSV on histone and chaperone protein expression. Cell fractionation and confocal microscopy was used to illustrate the presence of CTSV in the nuclear compartment.

Results: In this work we have identified that CTSV has an impact on breast cancer cell proliferation, with CTSV depleted cells exhibiting delayed progression through the G2/M phase of the cell cycle. Further investigation has revealed that CTSV can control nuclear expression levels of histones H3 and H4 via regulating protein expression of their chaperone sNASP. We have discovered that CTSV is localised to the nuclear compartment in breast tumour cells, mediated by a bipartite nuclear localisation signal (NLS) within the CTSV sequence and that nuclear CTSV is required for cell cycle progression and histone stability in breast tumour cells.

Discussion: Collectively these findings support the hypothesis that targeting CTSV may have utility as a novel therapeutic target in ER+ breast cancer by impairing cell cycle progression via manipulating histone stabilisation.

Item Type: Article
Subjects: Eprint Open STM Press > Multidisciplinary
Depositing User: Unnamed user with email admin@eprint.openstmpress.com
Date Deposited: 08 Nov 2023 08:04
Last Modified: 08 Nov 2023 08:04
URI: http://library.go4manusub.com/id/eprint/1611

Actions (login required)

View Item
View Item